Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

Stage III Non-small-cell Lung Cancer Clinical Trial

Official title:
A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

Status Active, not recruiting

Clinical Trial Summary

The phase II, randomised Study is to explore the efficacy and safety of nivolumab as consolidation therapy in patients with locally advanced, unresectable non-small cell lung cancer (stage III) who have not progressed following neoadjuvant chemotherapy plus nivolumab and definitive concurrent chemoradiation therapy

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Stage III Non-small-cell Lung Cancer

Clinical Trial Details

NCT number	NCT04085250
Study type	Interventional
Source	Sun Yat-sen University
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	November 28, 2019
Completion date	January 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03742687` - Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC	N/A
Completed	`NCT01733589` - Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC	Phase 1/Phase 2
Recruiting	`NCT04325763` - A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)	Phase 3
Active, not recruiting	`NCT03589547` - Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung	Phase 2
Not yet recruiting	`NCT04304638` - Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
Active, not recruiting	`NCT01576796` - Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Patients With Stage III Non-small-cell Lung Cancer	Phase 2
Recruiting	`NCT04441138` - Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC	Phase 2
Not yet recruiting	`NCT04181372` - A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer	Phase 2
Terminated	`NCT03871153` - Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer	Phase 2
Completed	`NCT05331833` - Omitting Clinical Target Volume of Unresectable Stage III Non-small-cell Lung Cancer.